Publication:
Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.

dc.contributor.authorRogozinski, Sophia
dc.contributor.authorKlietz, Martin
dc.contributor.authorRespondek, Gesine
dc.contributor.authorOertel, Wolfgang H
dc.contributor.authorGrothe, Michel J
dc.contributor.authorPereira, Joana B
dc.contributor.authorHöglinger, Günter U
dc.date.accessioned2023-05-03T13:42:12Z
dc.date.available2023-05-03T13:42:12Z
dc.date.issued2022-04-01
dc.description.abstractTo study in vivo gray matter (GM) volumes of the nucleus basalis of Meynert (nbM) in different parkinsonian syndromes and assess their relationship with clinical variables. T1-weighted magnetic resonance images from patients with progressive supranuclear palsy (PSP, N = 43), multiple system atrophy (MSA, N = 23), Parkinson's disease (PD, N = 26), and healthy controls (HC, N = 29) were included. T1-weighted images were analyzed using a voxel-based morphometry approach implemented in the VBM8 toolbox, and nbM volumes were extracted from the spatially normalized GM images using a cyto-architectonically-defined nbM mask in stereotactic standard space. NbM volumes were compared between groups, while controlling for intracranial volume. Further, within each group correlation analyses between nbM volumes and the Mini Mental Status Examination (MMSE), Hoehn and Yahr stage, PSP Rating Scale, Unified Parkinson's Disease Rating Scale part III and Frontal Assessment Battery scores were performed. Significantly lower nbM volumes in patients with PSP and PD compared to HC or patients with MSA were found. No significant correlations between MMSE and nbM volumes were detected in any of the subgroups. No significant correlations were found between clinical scores and nbM volumes in PSP or other groups. nbM volumes were reduced both in PD and PSP but not in MSA. The lack of significant correlations between nbM and cognitive measures suggests that other factors, such as frontal atrophy, may play a more important role than subcortical cholinergic atrophy in PSP patients. These results may indicate that other drug-targets are needed to improve cognitive function in PSP patients.
dc.identifier.doi10.3389/fnagi.2022.851788
dc.identifier.issn1663-4365
dc.identifier.pmcPMC9012106
dc.identifier.pmid35431891
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012106/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fnagi.2022.851788/pdf
dc.identifier.urihttp://hdl.handle.net/10668/20635
dc.journal.titleFrontiers in aging neuroscience
dc.journal.titleabbreviationFront Aging Neurosci
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number851788
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectParkinson’s disease
dc.subjectcholinergic innervation
dc.subjectmultiple system atrophy
dc.subjectnucleus basalis of Meynert
dc.subjectprogressive supranuclear palsy
dc.subjectsubcortical dementia
dc.subjectvoxel-based morphometry
dc.titleReduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9012106.pdf
Size:
772.51 KB
Format:
Adobe Portable Document Format